Findings

What do systematic reviews say?

321 questions · 328 findings · 23 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 119 · 36.3%GRADE not reported 15 · 4.6%Very low 64 · 19.5%Low 72 · 22%Moderate 41 · 12.5%High 17 · 5.2%

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Incidence of serious adverse events ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
RR 1.16 [0.79, 1.71]
1 study · 99 participants
Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Incidence of serious adverse events ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

IVIg vs no IVIG

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs no etanercept

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cyclosporin vs no cyclosporin

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cyclosporin vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cyclosporin vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs no corticosteroid use

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found